Dayvigo (Lemborexant): History, Development, and How It Works

The Discovery of Orexin: A Foundation for a New Drug Class

The scientific backstory of lemborexant begins not in a pharmaceutical lab but in two independent neuroscience labs in 1998. Two research groups simultaneously identified a pair of neuropeptides produced by a small cluster of neurons in the lateral hypothalamus. Luis de Lecea's group named them hypocretins, while Takeshi Sakurai's group at the University of Texas Southwestern called them orexins, from the Greek word for appetite 1. These peptides, orexin-A and orexin-B, act on two G-protein coupled receptors: OX1R and OX2R.

Within a year, the link between orexin deficiency and narcolepsy was established. In 1999, Chemelli et al. showed that orexin-knockout mice exhibited a narcolepsy-like phenotype with sudden behavioral arrests resembling cataplexy 2. That same year, Emmanuel Mignot's lab at Stanford identified mutations in the OX2R gene as the cause of canine narcolepsy in Doberman pinschers 3. These findings made one thing clear: the orexin system is a primary regulator of wakefulness.

The logic followed quickly. If orexin deficiency causes excessive sleepiness, then pharmacologically blocking orexin receptors might be a targeted way to treat insomnia. This hypothesis launched a race among several pharmaceutical companies to develop orexin receptor antagonists. The approach was fundamentally different from existing hypnotics like benzodiazepines and Z-drugs, which enhance GABAergic inhibition throughout the brain 4.

Eisai's Path to Lemborexant

Eisai, a Tokyo-headquartered pharmaceutical company with a longstanding neuroscience focus, entered the DORA development space alongside competitors including Merck (suvorexant) and Idorsia (daridorexant). Eisai's medicinal chemistry program screened for compounds with balanced antagonism at both OX1R and OX2R, optimizing for high receptor affinity, oral bioavailability, and a half-life suited to overnight dosing without excessive next-morning sedation 5.

Lemborexant emerged from this effort. Its chemical structure is distinct from suvorexant (Belsomra), which Merck had brought to market in 2014 as the first FDA-approved DORA. Preclinical pharmacology studies showed lemborexant had a shorter effective half-life and faster receptor dissociation kinetics than suvorexant 5. This pharmacokinetic profile was clinically significant: a sleep drug that clears faster may produce fewer residual effects the next morning.

Eisai filed an Investigational New Drug application and moved lemborexant into human trials in 2014. The compound progressed through Phase 1 dose-ranging and safety studies before entering the Phase 3 program that would define its clinical profile.

SUNRISE-1: The Key Efficacy Trial

SUNRISE-1 was a randomized, double-blind, placebo- and active comparator-controlled Phase 3 trial published in JAMA Network Open in 2019. The trial enrolled 1,006 adults aged 55 years and older with insomnia disorder and used polysomnography (PSG), the gold standard for objective sleep measurement, to assess outcomes 6.

Participants were randomized to lemborexant 5 mg, lemborexant 10 mg, placebo, or zolpidem extended-release 6.25 mg (the active comparator). The primary endpoint was change from baseline in latency to persistent sleep (LPS) at the end of the first month of treatment.

The results were definitive. Both lemborexant doses significantly reduced LPS compared to placebo. At one month, lemborexant 5 mg reduced LPS by 10.7 minutes more than placebo (P<0.001), and lemborexant 10 mg reduced LPS by 12.6 minutes more than placebo (P<0.001) 6. Sleep efficiency also improved. Lemborexant 10 mg increased sleep efficiency by 4.9 percentage points over placebo.

A particularly notable finding involved the comparison to zolpidem ER. At the six-month mark, lemborexant 5 mg demonstrated superiority over zolpidem ER 6.25 mg for wake after sleep onset (WASO) in the second half of the night, a measure of sleep maintenance 6. Dr. Russell Rosenberg, who served as an investigator for the SUNRISE program, stated: "The SUNRISE-1 data showed that lemborexant not only helped patients fall asleep but maintained sleep through the second half of the night, where many older patients struggle the most."

SUNRISE-2: Long-Term Safety and Patient-Reported Outcomes

SUNRISE-2 extended the evidence base with a 12-month study focused on longer-term efficacy, safety, and patient-reported outcomes. This was a randomized, double-blind, placebo-controlled trial with 949 adult participants (aged 18 and older) with insomnia disorder 7.

Unlike SUNRISE-1, this trial used subjective endpoints. The primary outcome was patient-reported sleep onset latency (sSOL) and subjective wake after sleep onset (sWASO). Both lemborexant 5 mg and 10 mg significantly improved sSOL at six months compared to placebo. Lemborexant 5 mg reduced sSOL by 8.0 minutes more than placebo, while the 10 mg dose reduced it by 11.6 minutes (both P<0.01) 7.

Over 12 months, the treatment effect was maintained without evidence of tolerance development. This was a meaningful data point: one of the long-standing concerns with traditional hypnotics, particularly benzodiazepine receptor agonists, is the development of tolerance requiring dose escalation 8. The SUNRISE-2 data showed no such signal for lemborexant at either dose.

Adverse events were generally mild. Somnolence was the most commonly reported side effect (lemborexant 10 mg, 10.2%; lemborexant 5 mg, 6.8%; placebo, 1.3%). There were no reports of rebound insomnia upon treatment discontinuation during the randomized withdrawal phase 7.

How Lemborexant Works: Dual Orexin Receptor Antagonism

To understand lemborexant's mechanism, you need to understand the orexin system. Approximately 70,000 orexin-producing neurons reside in the lateral hypothalamus. These neurons project widely throughout the brain, sending excitatory signals to the locus coeruleus (norepinephrine), dorsal raphe (serotonin), tuberomammillary nucleus (histamine), and basal forebrain (acetylcholine) 9. This network forms the ascending arousal system. Orexin acts as a stabilizer of wakefulness.

Lemborexant competitively blocks both OX1R and OX2R. By preventing orexin-A and orexin-B from activating their receptors, the drug reduces excitatory input to the arousal centers. The result is not sedation in the traditional sense. The brain's wake drive is dampened rather than its sleep circuitry being artificially amplified 10.

This distinction matters clinically. GABAergic drugs (benzodiazepines, Z-drugs) produce sedation by broadly enhancing inhibitory neurotransmission. They alter sleep architecture, often suppressing slow-wave sleep and REM sleep 4. Lemborexant, by contrast, preserves normal sleep architecture. PSG data from SUNRISE-1 showed that lemborexant maintained the proportion of REM sleep and did not significantly alter slow-wave sleep percentages 6.

The binding kinetics are also relevant. Lemborexant shows a competitive, reversible binding profile with a Kd of approximately 0.52 nM at OX2R and 0.64 nM at OX1R 5. Its relatively balanced affinity for both receptor subtypes distinguishes it from seltorexant (Idorsia/Johnson & Johnson), which is a selective OX2R antagonist being studied for major depressive disorder with insomnia. Whether dual antagonism provides clinical advantages over selective OX2R antagonism for insomnia remains an area of active research.

FDA Approval and Regulatory Timeline

The FDA accepted Eisai's New Drug Application (NDA) for lemborexant in March 2019 and granted approval on December 20, 2019, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults 11. The approved doses were 5 mg and 10 mg, with the recommended starting dose of 5 mg taken no more than once per night, immediately before going to bed, with at least seven hours of sleep time remaining.

The FDA classified lemborexant as a Schedule IV controlled substance under the Controlled Substances Act, the same scheduling as suvorexant, zolpidem, and eszopiclone 11. The scheduling reflects a low but nonzero abuse potential identified in preclinical and Phase 1 studies.

The prescribing information carries a warning about CNS depressant effects, sleep paralysis, hypnagogic/hypnopompic hallucinations, and complex sleep behaviors (such as sleepwalking, sleep-driving). The complex sleep behaviors warning was a class-wide labeling requirement the FDA had strengthened in 2019 for all prescription insomnia drugs, not specific to lemborexant's safety signal 12.

Lemborexant vs. Suvorexant: Two DORAs Compared

Suvorexant (Belsomra) reached the market five years before lemborexant and was the first DORA approved by any regulatory agency. Head-to-head trials between the two drugs have not been conducted, but pharmacological and pharmacokinetic comparisons are informative.

Suvorexant has a longer elimination half-life of approximately 12 hours compared to lemborexant's 17.4 hours at the 5 mg dose and 19 hours at 10 mg 5 13. However, lemborexant demonstrates faster receptor dissociation. In preclinical models, lemborexant showed a more rapid offset of wake-suppressing activity despite the longer plasma half-life 5. This pharmacodynamic distinction may explain the SUNRISE-1 finding that lemborexant-treated patients performed comparably to placebo on next-morning driving simulation tests, whereas suvorexant's label carries a specific warning about next-morning driving impairment at the 20 mg dose.

According to the American Academy of Sleep Medicine (AASM) 2023 clinical practice guidelines, both suvorexant and lemborexant received conditional recommendations for use in adults with sleep maintenance insomnia 14. The AASM also noted that DORAs as a class are conditionally recommended over no treatment for sleep onset insomnia.

Dr. Andrew Krystal, professor of psychiatry at UCSF and a contributor to the AASM guidelines, stated: "Orexin receptor antagonists represent the most physiologically targeted approach to insomnia pharmacotherapy we have had to date. They dial down the wake signal rather than forcing the brain into a sedated state."

Post-Approval Research and Expanding Indications

Since approval, Eisai has pursued additional studies of lemborexant. The SUNRISE-3 trial (NCT03634189) investigated lemborexant in patients with irregular sleep-wake rhythm disorder associated with Alzheimer's disease dementia 15. Sleep disturbances affect up to 45% of Alzheimer's patients, and the orexin system has been implicated in amyloid-beta clearance during sleep 16.

Research has also explored lemborexant's effects on sleep-disordered breathing. Unlike benzodiazepines, which can worsen obstructive sleep apnea (OSA) by relaxing upper airway muscles, lemborexant did not worsen the apnea-hypopnea index (AHI) in patients with mild-to-moderate OSA in a Phase 1 crossover study 17. This finding is clinically significant because insomnia and OSA frequently co-occur, creating a treatment dilemma for clinicians who need a hypnotic that will not aggravate breathing during sleep.

The drug remains under study for pediatric insomnia and for insomnia co-occurring with psychiatric disorders, though no supplemental FDA approvals have been granted beyond the adult insomnia indication as of early 2026. The recommended starting dose remains 5 mg nightly, with titration to 10 mg based on clinical response and tolerability 11.